E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« USPTO News: Additional Application Types Eligible for Participation in PPH Between USPTO and EPO | Main | ACI Pharmaceutical and Biotech Patent Claim Drafting Conference »

December 11, 2008

Comments

Thanks very much for this post. The presentation is something I would never find out about otherwise and your analysis of the problems with the USPTO approach is very helpful. My own view is that Bilski is a mess. They wanted to step back on business method patents, which is fine in itself, but the majority opinion is an incoherent hodge podge of doctrines that will have unintended consequences well outside the business methods area. (I can't blame the CAFC - the incoherence starts with the USSC computer trilogy.) From your post, it looks like we're already seeing the beginning.

The comments to this entry are closed.

April 2017

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30